Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Interaction of BR6001-1 and BR6001-2 in Healthy Volunteers
NCT06165237Phase 1Completed
- Sponsor
- Boryung
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BR6001-1 and br6001-2 in gastric ulcer and duodenal ulcer, sponsored by Boryung. Primary endpoints: Area under the Plasma Concentration-Time Curve During Dosing Interval (tau) at Steady State, Maximum Concentration of Drug in Plasma at Steady State and 2 more. Started Mar 2023; status: completed.
02
Drugs
BR6001-1br6001-2
03
Conditions
gastric ulcerduodenal ulcer
Beyond the preview
Go deeper on NCT06165237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06165237.